Renin-Angiotensin-System (RAS)-Acting Agents Market Report 2026

Renin-Angiotensin-System (RAS)-Acting Agents Market Overview

• Renin-Angiotensin-System (RAS)-Acting Agents market size has reached to $6.11 billion in 2025 • Expected to grow to $7.96 billion in 2030 at a compound annual growth rate (CAGR) of 5.4% • Growth Driver: Surge In Increasing Prevalence Of Hypertension Fueling The Growth Of The Market Due To Rising Unhealthy Lifestyles • Market Trend: Innovative Therapies Enhancing Pediatric Heart Failure Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Renin-Angiotensin-System (RAS)-Acting Agents Market?

The renin-angiotensin system (RAS)-acting agents are a class of medications that regulate blood pressure, fluid balance, and vascular resistance by targeting various components of the renin-angiotensin system, which plays a crucial role in cardiovascular and renal function. These agents are commonly prescribed to treat conditions like hypertension, heart failure, and chronic kidney disease by either blocking the production of angiotensin II or inhibiting its effects on blood vessels. The main drug classes in renin-angiotensin-system (RAS)-acting agents are angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), renin inhibitors, aldosterone antagonists, and others. Angiotensin-converting enzyme (ACE) inhibitors are medications that block the enzyme responsible for converting angiotensin I to angiotensin II, a substance that narrows blood vessels and increases blood pressure. It is used for various indications, such as hypertension, heart failure, chronic kidney disease, diabetic nephropathy, and coronary artery disease, and is distributed through hospital pharmacies, retail pharmacies, online pharmacies, and specialty clinics catering to various end users, including hospitals, research institutes, pharmaceutical companies, and others.

What Is The Renin-Angiotensin-System (RAS)-Acting Agents Market Growth Forecast?

The renin-angiotensin-system (ras)-acting agents market size is expected to see strong growth in the next few years. It will grow to $7.96 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to chronic kidney disease burden, demand for cardiometabolic drugs, improved treatment adherence, expansion in emerging markets, combination therapy approvals. Major trends in the forecast period include increasing use of combination antihypertensive therapies, growth of long-acting cardiovascular drugs, rising focus on renal protection therapies, expansion of generic RAS drug production, shift toward fixed-dose combinations.

Global Renin-Angiotensin-System (RAS)-Acting Agents Market Segmentation

1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes 2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics 4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users Subsegments: 1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril 2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan 3) By Renin Inhibitors: Aliskiren 4) By Aldosterone Antagonists: Spironolactone, Eplerenone 5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)

What Is The Driver Of The Renin-Angiotensin-System (RAS)-Acting Agents Market?

The increasing prevalence of hypertension is expected to propel the growth of the renin-angiotensin system (RAS)-acting agents market going forward. Hypertension, or high blood pressure, is a chronic medical condition in which the force of blood against the artery walls is consistently too high. The prevalence of hypertension is rising due to unhealthy diets, particularly those high in salt and processed foods, which contribute to elevated blood pressure and strain on the cardiovascular system. Renin-angiotensin system (RAS)-acting agents help reduce the prevalence of hypertension by regulating blood pressure through the inhibition of angiotensin II, a hormone that constricts blood vessels and increases fluid retention, thereby promoting vasodilation and lowering blood pressure. For instance, in September 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, an estimated 1.4 billion adults aged 30–79 worldwide were living with hypertension in 2024, accounting for about 33% of people in this age group. Therefore, the increasing prevalence of hypertension is driving the growth of the renin-angiotensin system (RAS)-acting agents market.

Key Players In The Global Renin-Angiotensin-System (RAS)-Acting Agents Market

Major companies operating in the renin-angiotensin-system (ras)-acting agents market are Novartis AG, AstraZeneca plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Pfizer Inc., Sanofi S.A., Bayer AG, Daiichi Sankyo Company Limited, Astellas Pharma Inc., Biocon Limited, Lupin Limited, Sun Pharmaceutical Industries Ltd., Mylan N.V., Zydus Lifesciences Limited

Global Renin-Angiotensin-System (RAS)-Acting Agents Market Trends and Insights

Major companies operating in the renin-angiotensin system (RAS)-acting agents market are focusing on developing novel renin-angiotensin system (RAS) inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors, to enhance efficacy, minimize side effects, improve patient compliance, and target hypertension, heart failure, and kidney diseases. An angiotensin-converting enzyme (ACE) inhibitor is a medication that lowers blood pressure by blocking the enzyme that converts angiotensin I to angiotensin II, a substance that narrows blood vessels. For instance, in November 2023, Proveca Ltd., a UK-based pharmaceutical company, received a grant from the European Commission for pediatric use marketing authorization (PUMA) for Aqumeldi (enalapril maleate) orodispersible tablets indicated for the treatment of heart failure in children from birth to less than 18 years. Aqumeldi is an angiotensin-converting enzyme (ACE) inhibitor that treats pediatric heart failure patients by blocking the angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, thereby relaxing blood vessels, improving blood flow, and decreasing the workload on the heart.

What Are Latest Mergers And Acquisitions In The Renin-Angiotensin-System (RAS)-Acting Agents Market?

In February 2023, AstraZeneca, a UK-based pharmaceutical company, acquired CinCor Pharma for $1.3 billion. With this acquisition, AstraZeneca aims to strengthen its cardiorenal pipeline by adding CinCor’s lead drug, baxdrostat (CIN-107), a selective aldosterone synthase inhibitor (ASI) designed to lower blood pressure in treatment-resistant hypertension. CinCor Pharma is a US-based biopharmaceutical company developing renin-angiotensin-system (RAS)-acting agents, including baxdrostat, a selective aldosterone synthase inhibitor for resistant hypertension.

Regional Insights

North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Renin-Angiotensin-System (RAS)-Acting Agents Market?

The renin-angiotensin system (RAS)-acting agents market consists of sales of enalapril, lisinopril, ramipril, and captopril. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Renin-Angiotensin-System (RAS)-Acting Agents Market Report 2026?

The renin-angiotensin-system (ras)-acting agents market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the renin-angiotensin-system (ras)-acting agents industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.